Physician profile
Sharon E Hodges
NPI 1275513244
$1,437.62
in general payments reported to CMS, 2019-2025
24 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.80 · 2020: $165 · 2021: $344 · 2022: $333 · 2023: $220 · 2024: $167 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.54 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $400.05 | 2020-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $148.97 | 2020-2023 | |
| Mayne Pharma Commercial LLC | $125.54 | 2021-2023 | |
| Millicent US INC | $99.39 | 2019-2025 | Intrarosa, Femring |
| Aspira Women'S Health INC | $78.66 | 2022 | |
| Agile Therapeutics, INC. | $59.30 | 2021-2022 | |
| Boston Scientific Corporation | $52.52 | 2021-2025 | Axonics |
| Pfizer INC. | $52.48 | 2024 | |
| Merck Sharp & Dohme LLC | $46.24 | 2020-2024 | Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $44.64 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $43.18 | 2024 | Gemtesa, Myfembree |
| Therapeuticsmd, INC. | $41.31 | 2019-2021 | |
| Intuitive Surgical, INC. | $38.67 | 2023 | Da Vinci Surgical System |
| Axonics, INC. | $29.56 | 2021 | |
| Davol INC. | $24.19 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21.10 | 2021 | |
| Scynexis, INC. | $19.54 | 2022 | |
| Coopersurgical, INC. | $19.30 | 2025 | Endosee |
| Novo Nordisk INC | $17.89 | 2020 | |
| Evofem Biosciences, INC. | $17.34 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.12 | 2020 | |
| Meditrina | $15.56 | 2022 | |
| Allergan, INC. | $13.54 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.